(1) CAF‐targeted therapies: TKIs constitute viable alternative treatment options for HRD tumors, given the abundance of FGFR1+PDGFRΒ+ myCAFs within the HRD TIME. This evidence concerns the gene FGFR1 and hypoparathyroidism-retardation-dysmorphism syndrome.